These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 25092043)

  • 61. Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study.
    Neukam K; Espinosa N; Collado A; Delgado-Fernández M; Jiménez-Aguilar P; Rivero-Juárez A; Hontañón-Antoñana V; Gómez-Berrocal A; Ruiz-Morales J; Merino D; Carrero A; Téllez F; Ríos MJ; Hernández-Quero J; de Lagarde-Sebastián M; Pérez-Camacho I; Vera-Méndez F; Macías J; Pineda JA;
    PLoS One; 2016; 11(5):e0155842. PubMed ID: 27195797
    [TBL] [Abstract][Full Text] [Related]  

  • 62. HIV/HCV co-infection: natural history.
    Puoti M; Prestini K; Putzolu V; Zanini B; Baiguera C; Antonini MG; Pagani P; Airoldi M; Carosi G
    J Biol Regul Homeost Agents; 2003; 17(2):144-6. PubMed ID: 14518713
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection.
    Torriani FJ; Ribeiro RM; Gilbert TL; Schrenk UM; Clauson M; Pacheco DM; Perelson AS
    J Infect Dis; 2003 Nov; 188(10):1498-507. PubMed ID: 14624375
    [TBL] [Abstract][Full Text] [Related]  

  • 64. High serum HCV RNA in chronic hepatitis C patients coinfected with HIV despite successful antiretroviral therapy.
    Barreiro P; Labarga P; de Mendoza C; Benítez-Gutiérrez L; Fernandez-Montero JV; Peña JM; Soriano V
    Antivir Ther; 2016; 21(6):489-494. PubMed ID: 26887981
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hepatitis B virus and hepatitis C virus infection among HIV-1-infected injection drug users in Dali, China: prevalence and infection status in a cross-sectional study.
    Dong Y; Qiu C; Xia X; Wang J; Zhang H; Zhang X; Xu J
    Arch Virol; 2015 Apr; 160(4):929-36. PubMed ID: 25616842
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Coinfection with HIV and hepatitis C virus in injection drug users and minority populations.
    Strader DB
    Clin Infect Dis; 2005 Jul; 41 Suppl 1():S7-13. PubMed ID: 16265618
    [TBL] [Abstract][Full Text] [Related]  

  • 67. How effective is HAART in HCV and HIV coinfection?
    Núñez M; Soriano V
    AIDS; 2004 Oct; 18(15):2081-4. PubMed ID: 15577630
    [No Abstract]   [Full Text] [Related]  

  • 68. Enhancing current human immunodeficiency virus/hepatitis B and human immunodeficiency virus/hepatitis C virus co-infection management.
    Huang ZL; Chen DB; Gao ZL; Lin BL
    Chin Med J (Engl); 2020 Dec; 133(23):2890-2891. PubMed ID: 33273344
    [No Abstract]   [Full Text] [Related]  

  • 69. Barriers to hepatitis C virus elimination in MSM living with HIV: The high risk of reinfection. Case study: A patient with 6 episodes.
    Laguno M; Martínez-Rebollar M; de la Mora L; Pérez-Del-Pulgar S; Mallolas J
    Gastroenterol Hepatol; 2019 Nov; 42(9):555-556. PubMed ID: 31324465
    [No Abstract]   [Full Text] [Related]  

  • 70. Impact of immunosuppression caused by HIV infection on the replication of hepatitis C virus.
    Soriano V; Bravo R; Mas A; García-Samaniego J; Guiérrez M; González-Lahoz J
    Vox Sang; 1995; 69(3):259-60. PubMed ID: 8578743
    [No Abstract]   [Full Text] [Related]  

  • 71. Hepatitis C virus's next top models?
    Paul D; Bartenschlager R
    Nat Microbiol; 2016 Jan; 1():15018. PubMed ID: 27571762
    [No Abstract]   [Full Text] [Related]  

  • 72. The Stanley Wilkinson Oration.
    Lewin S
    Aust Orthod J; 2016 May; 32(1):114-8. PubMed ID: 27468599
    [No Abstract]   [Full Text] [Related]  

  • 73. Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection.
    Jabara CB; Hu F; Mollan KR; Williford SE; Menezes P; Yang Y; Eron JJ; Fried MW; Hudgens MG; Jones CD; Swanstrom R; Lemon SM
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6079-92. PubMed ID: 25092699
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
    Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
    Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing.
    Margeridon-Thermet S; Le Pogam S; Li L; Liu TF; Shulman N; Shafer RW; Najera I
    PLoS One; 2014; 9(8):e105569. PubMed ID: 25140696
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Influence of hepatitis C virus coinfection on CD4⁺ T cells of HIV-infected patients receiving HAART.
    Shmagel KV; Saidakova EV; Korolevskaya LB; Shmagel NG; Chereshnev VA; Anthony DD; Lederman MM
    AIDS; 2014 Oct; 28(16):2381-8. PubMed ID: 25111083
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients.
    Sherman KE; Guedj J; Shata MT; Blackard JT; Rouster SD; Castro M; Feinberg J; Sterling RK; Goodman Z; Aronow BJ; Perelson AS
    Sci Transl Med; 2014 Jul; 6(246):246ra98. PubMed ID: 25101888
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin.
    Hedskog C; Doehle B; Chodavarapu K; Gontcharova V; Crespo Garcia J; De Knegt R; Drenth JP; McHutchison JG; Brainard D; Stamm LM; Miller MD; Svarovskaia E; Mo H
    Hepatology; 2015 Feb; 61(2):471-80. PubMed ID: 25099344
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Viral entry inhibition: too late for hepatitis C, but promising for other viral infections.
    Pawlotsky JM
    Gut; 2015 Mar; 64(3):362-4. PubMed ID: 25098973
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.